Five varieties of Shandong Province start the renewal negotiation

Wen Feng mound On January 13, Shandong Medical Insurance Bureau issued the notice on carrying out the renewal work of drug contract negotiation in Shandong Province, encouraging the renewal enterprises of five major varieties such as enacep for injection and the newly listed similar drugs to voluntarily declare and negotiate On August 1, 2018, Shandong Province included 14 kinds of drugs into the payment scope of serious illness insurance, which are: regofinib, oxitinib mesylate, alfatinib maleate, clozatinib capsule, acitinib tablet, enacepp for injection, nilotinib capsule, lucotinib phosphate, pezopanil tablet, octreotide acetate microsphere injection, shaprotterin hydrochloride, hydrochloric acid Dalatawei tablets, paclitaxel for injection (albumin binding) (clenbuterol, Abraxane), doxorubicin hydrochloride liposome injection (dometaxel, ribado, Lixing) The agreement is valid until December 31, 2019 In order to ensure the stability of the policy and the treatment level of the patients, it is very important to do a good job in the renewal of the drug Contract negotiated by the province The regulations of Shandong Medical Insurance Bureau are as follows: 1、 Scope Drugs included in the payment scope of serious illness insurance in Shandong Province through negotiation in our province, which have expired the agreement and have not been included in the national basic medical insurance drug catalog (including negotiation drugs) for treatment guarantee, specifically including enacept for injection, saprotterin hydrochloride, dalatavir hydrochloride, paclitaxel for injection (albumin binding type), doxorubicin hydrochloride liposome injection Any pharmaceutical manufacturer (Supplier) who intends to renew the agreement can voluntarily submit materials and apply for renewal of the agreement For the newly marketed drugs of the same kind (with the same general name), they can also be declared voluntarily 2、 Submission of materials Fill in the application form for signing (renewing) the negotiated drug agreement in Shandong Province (attachment), and provide relevant materials such as the current price of the corresponding drugs, the space for pre price reduction for signing this agreement, the lowest price in China, the text of the agreement signed by the drug in other provinces, and the sales of the whole province in 2019 (including the number of drug users, sales volume, etc.).